Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Chrisp, E. Sorkin (1991)
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.Drugs & aging, 1 6
T. Mazzei, E. Mini, M. Eandi, E. Reali, L. Fioretto, R. Bartoletti, M. Rizzo, G. Calabrò, P. Periti (1989)
Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.Drugs under experimental and clinical research, 15 8
F. Chu, M. Jayson, M. Dineen, R. Perez, R. Harkaway, R. Tyler (2002)
A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.The Journal of urology, 168 3
M.S. Khan, A. O'brien (1998)
An Evaluation of Pharmacokinetics and Pharmacodynamics of Leuprorelin Acetate 3M-Depot in Patients with Advanced and Metastatic Carcinoma of the ProstateUrologia Internationalis, 60
H. Ueno, S. Matsuo (1991)
High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite.Journal of chromatography, 566 1
J. Fowler, S. Bigler, J. Kolski, David Yee (1998)
Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinomaCancer, 82
L. Sennello, Richard Finley, S. Chu, Cheryl Jagst, Devorah Max, Douglas Rollins, K. Tolman (1986)
Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration.Journal of pharmaceutical sciences, 75 2
S. Stoch, Robert Parker, Liping Chen, Glenn Bubley, Yoo-Joung Ko, Aimee Vincelette, S. Greenspan (2001)
Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.The Journal of clinical endocrinology and metabolism, 86 6
L. Swanson, J. Seely, M. Garnick (1988)
Gonadotropin-releasing hormone analogs and prostatic cancer.Critical reviews in oncology/hematology, 8 1
M. Bolla, D. González, P. Warde, J. Dubois, R. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, T. Gil, L. Collette, M. Piérart (1997)
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.The New England journal of medicine, 337 5
R. Santen, L. Demers, D. Max, J. Smith, B. Stein, L. Glodé (1984)
Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma.The Journal of clinical endocrinology and metabolism, 58 2
H. Ravivarapu, K. Moyer, R. Dunn (2000)
Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate.Journal of pharmaceutical sciences, 89 6
R. Sharifi, M. Soloway (1990)
Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancerJ Urol, 143
Jeremy Wright, Sally Leonard, Cynthia Stevenson, James Beck, Guohua Chen, Rose Jao, Paul Johnson, Joe Leonard, Roman Skowronski (2001)
An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.Journal of controlled release : official journal of the Controlled Release Society, 75 1-2
J. Moul, K. Civitelli (2001)
Managing advanced prostate cancer with Viadur (leuprolide acetate implant).Urologic nursing, 21 6
M. Pilepich, W. Sause, W. Shipley, J. Krall, C. Lawton, D. Grignon, M. al-Sarraf, Ross Abrams, Richard Caplan, Madhu John, Marvin Rotman, James Cox, R. Doggett, Philip Rubin, M. Soloway (1995)
Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.Urology, 45 4
L. Glodé, J. Smith (1987)
Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.The Journal of urology, 137 1
J. Smith, R. Urry (1985)
Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue.The Journal of urology, 133 4
(2000)
Lupron Depot® 4 month 30mg: package insert prescribing information
JACKSON Fowler, Michael Flanagan, Donald Gleason, Ira Klimberg, James Gottesman, Roohollah Sharifi (2000)
Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.Urology, 55 5
L. Glodé (1986)
The biology of gonadotropin-releasing hormone and its analogs.Urology, 27 1 Suppl
M. Cukierski, Paul Johnson, J. Beck (2001)
Chronic (60-Week) Toxicity Study of DUROS Leuprolide Implants in DogsInternational Journal of Toxicology, 20
(2002)
Viadur® (leuprolide acetate implant) prescribing information. Package insert
J. Rajfer, R. Swerdloff, D. Heber (1984)
Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.Fertility and sterility, 42 5
P. Periti, T. Mazzei, E. Mini (2002)
Clinical Pharmacokinetics of Depot LeuprorelinClinical Pharmacokinetics, 41
JACKSON Fowler (2001)
Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer.Urology, 58 3
J. Shaheen, M. Amin, J. Harty (1993)
Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist.Urology, 42 5
(1984)
Leuprolide versus diethylstilboestrol for metastatic prostate cancerN Engl J Med, 311
Michael Naughton, J. Picus (2002)
Advanced Prostate CancerAmerican Journal of Cancer, 1
M. Naughton, J. Picus (2002)
Advanced prostate cancer: a state-of-the-art guide to pharmacological managementAm J Cancer, 1
JACKSON Fowler, James Gottesman, C. Reid, Gerald Andriole, M. Soloway (2000)
Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.The Journal of urology, 164 3 Pt 1
L. Denis (1998)
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.Urology, 51 5A Suppl
B. Hellerstedt, K. Pienta (2002)
The Current State of Hormonal Therapy for Prostate CancerCA: A Cancer Journal for Clinicians, 52
G. Plosker, R. Brogden (1994)
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.Drugs, 48 6
T. Mazzei, E. Mini, M. Rizzo, P. Periti (1990)
Human Pharmacokinetic and Pharmacodynamic Profiles of Leuprorelin Acetate Depot in Prostatic Cancer PatientsJournal of International Medical Research, 18
M. Eisenberger, P. O'dwyer, M. Friedman (1986)
Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 4 3
H. Daniell, S. Dunn, D. Ferguson, G. Lomas, Z. Niazi, P. Stratte (2000)
Progressive osteoporosis during androgen deprivation therapy for prostate cancer.The Journal of urology, 163 1
J. Wright, G. Chen, M. Cukierski (1998)
Duros™ leuprolide implant for continuous one-year treatment of prostate cancerProceedings of the Controlled Release Society, 25
Conn Pm, W. Crowley (1991)
Gonadotropin-releasing hormone and its analogues.The New England journal of medicine, 324 2
Roohollah Sharifi, Mark Soloway (1990)
Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.The Journal of urology, 143 1
U. Tunn, U. Bargelloni, S. Cosciani, G. Fiaccavento, S. Guazzieri, F. Pagano (1998)
Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate CancerUrologia Internationalis, 60
J.E. Fowler (2000)
Use of the Duros® leuprolide implant in patients with prostate cancer: efficacy and safety results from two long-term phase I/II and III studiesJ Urol, 163
H. Okada, Y. Doken, Y. Ogawa, H. Toguchi (2004)
Preparation of Three-Month Depot Injectable Microspheres of Leuprorelin Acetate Using Biodegradable PolymersPharmaceutical Research, 11
A. Jemal, Andrea Thomas, Taylor Murray, M. Thun (2002)
Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 52
J. Fowler, J. Gottesman, S. Bardot, C. Reid, G. Andriole, P. Bernhard, I. Rivera-Ramirez, J. Libertino, M. Soloway (1999)
DUROS [trade mark sign] LEUPROLIDE IMPLANTABLE THERAPEUTIC SYSTEMS IN PATIENTS WITH ADVANCED PROSTATE CANCER: 14-MONTH RESULTS OF A PHASE I/II DOSE-RANGING STUDYThe Journal of Urology
▴ Leuprolide acetate (leuprorelin) is a luteinizing hormone-releasing hormone agonist used in the palliative treatment of advanced prostate cancer. A new, non-biodegradable, subcutaneous implant, containing 72mg leuprolide acetate (equivalent to 65mg leuprolide free base), uses osmotic pressure to deliver leuprolide at a constant rate over 1 year.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.